The global women’s health diagnostics market size is expected to reach USD 31.46 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 7.29% from 2025 to 2030. Rising adoption of point-of-care diagnostics and growing incidence of various chronic and lifestyle diseases are among the key factors stimulating the growth of the market. Besides this, introducing various awareness programs is also anticipated to work in favor the market during the forecast period. For instance, in 2014, the European Commission launched joint action for European Guide on Quality Improvement in Comprehensive Cancer Control.
Women’s health diagnostics is witnessing high growth due to increased funding from various organizations. For instance, in May 2015, Abcodia received funding of USD 8.0 million from Cambridge Innovative Capital, Scottish Equity Partners, Albion Ventures, and UCLB to launch Risk of Ovarian Cancer Algorithm (ROCA) test in the U.K. for early detection of ovarian cancer.
On the basis of end use, the market has been bifurcated into hospital & diagnostics centers and home. Hospitals and diagnostic centers accounted for a larger share in the market due to high number of visits to hospitals and more reliable detection.
The market in Asia Pacific is likely to witness significant growth over the coming years. The growth of the market can be attributed to increasing investments in healthcare, growing focus of international device manufacturers on strengthening their distribution networks within the region, and epidemiological shift from infectious diseases to chronic diseases within regional boundaries.
Request a free sample copy or view report summary: Women’s Health Diagnostics Market Report
Increasing investments by governments and private bodies and rising disposable income are providing a push to the market
Cancer accounted for the highest share in the market in 2024. The segment will register noteworthy growth during the forecast period owing to availability of early detection tests and government initiatives to tackle cancer
Prenatal testing is estimated to be the fastest growing segment during the same period owing to rising prevalence of prenatal diseases, increasing maternal age, surging healthcare expenditure, and development of advanced diagnostic tests
Geographically, North America dominated the market and accounted for the largest revenue share of 46.21% in 2024. It is anticipated to maintain its dominance through 2030, thanks to widening base of diagnostic and imaging centers, mounting cases of cancer, growing awareness about fertility testing, and spiraling adoption of point-of-care testing devices
Grand View Research has segmented the global women’s health diagnostics market report based on the application, end use, and region
Women’s Health Diagnostics Application Outlook (Revenue, USD Million, 2018 - 2030)
Cancer
Infectious diseases
Osteoporosis
Pregnancy & fertility
Prenatal
Women’s Health Diagnostics Application Outlook (Revenue, USD Million, 2018 - 2030)
Hospitals
Laboratory
Home care
Others
Women’s Health Diagnostics Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Sweden
Denmark
Norway
Asia Pacific
China
Japan
India
South Korea
Australia
Thailand
Latin America
Brazil
Argentina
Middle East and Africa (MEA)
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players of Women’s Health Diagnostics Market
F. Hoffmann-La Roche Ltd.
Hologic, Inc.
Quest Diagnostics Incorporated
Abbott
BD
Ge Healthcare
Koninklijke Philips N.V.
Aspira Women's Health
Thermo Fisher Scientific Inc.
Cardinal Health, Inc.
"The quality of research they have done for us has been excellent..."